The precision therapy market is rapidly expanding, driven by breakthroughs in mRNA-based treatments, viral vector-based gene therapies, and gene-modified cell therapies. A crucial component enabling these advancements is plasmid DNA (pDNA). However, pDNA manufacturing presents several challenges, such as manufacturing for small patient populations, meeting sustainability requirements, conforming to the exacting quality standards of regulatory agencies, and more.

This article highlights how contract development and manufacturing organizations (CDMOs) are emerging as key players in scaling up pDNA production efficiently. Global CDMO Syngene, for example, provides services across the entire mRNA manufacturing chain — from producing high-quality plasmids to lipid nanoparticle formulation and fill finish.